KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Amortization of Deferred Charges: 2009-2024

Historic Amortization of Deferred Charges for Pacira BioSciences (PCRX) over the last 8 years, with Dec 2024 value amounting to $3.1 million.

  • Pacira BioSciences' Amortization of Deferred Charges fell 25.48% to $626,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 6.64%. This contributed to the annual value of $3.1 million for FY2024, which is 4.47% up from last year.
  • Pacira BioSciences' Amortization of Deferred Charges amounted to $3.1 million in FY2024, which was up 4.47% from $3.0 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Amortization of Deferred Charges ranged from a high of $4.4 million in FY2022 and a low of $2.2 million during FY2020.
  • For the 3-year period, Pacira BioSciences' Amortization of Deferred Charges averaged around $3.5 million, with its median value being $3.1 million (2024).
  • Per our database at Business Quant, Pacira BioSciences' Amortization of Deferred Charges soared by 59.77% in 2022 and then crashed by 31.91% in 2023.
  • Over the past 5 years, Pacira BioSciences' Amortization of Deferred Charges (MRY) stood at $2.2 million in 2020, then increased by 27.74% to $2.8 million in 2021, then skyrocketed by 59.77% to $4.4 million in 2022, then plummeted by 31.91% to $3.0 million in 2023, then grew by 4.47% to $3.1 million in 2024.
  • Its last three reported values are $3.1 million in FY2024, $3.0 million for FY2023, and $4.4 million during FY2022.